Holen Sie sich die Stockscreener-App
2.55
4.08%
0.10
Handel nachbörslich:
2.58
0.03
+1.18%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IOVA?
Forum
Prognose
Aktiensplit
Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten
Wells Fargo Lowers Price Target for Iovance Biotherapeutics (IOVA) Amid Mixed Q2 Results: Is Amtagvi's Growth Enough to Justify the Downgrade? - AInvest
Wells Fargo Lowers Iovance Biotherapeutics (IOVA) PT to $14 Despite Strong Amtagvi Sales, Q2 Revenue Growth - Yahoo Finance
Is Iovance Biotherapeutics Inc. a momentum stock2025 Stock Rankings & Safe Capital Growth Plans - thegnnews.com
Iovance Biotherapeutics shares rise 2.04% premarket as private investment in oncology ventures surges. - AInvest
Iovance Biotherapeutics’ SWOT analysis: navigating challenges in cancer immunotherapy stock - Investing.com
Iovance Biotherapeutics shares rise 3.27% intraday as private investment in oncology ventures surges. - AInvest
Iovance Biotherapeutics (IOVA) Projected 2025 Revenue Up To US$300 Million - Yahoo Finance
Iovance Biotherapeutics' Earnings Call Highlights Growth, Revenue Up 22% to $60M - AInvest
Iovance Biotherapeutics’ Earnings Call Highlights Growth - TipRanks
Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight - The Malaysian Reserve
Iovance Soars on Amtagvi Success: What’s Next? - StocksToTrade
Iovance Biotherapeutics Surges on Promising Study Outcomes - timothysykes.com
AI Tools Suggest Iovance Biotherapeutics Inc. May Outperform This WeekBuy Alerts With Low Risk Confirmation Noted - 선데이타임즈
Published on: 2025-08-12 06:23:53 - beatles.ru
Iovance Biotherapeutics' Strategic Turnaround and Regulatory Hurdles: Is the Biotech Buyable at a 64% YTD Decline? - AInvest
Here's What Analysts Are Forecasting For Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) After Its Second-Quarter Results - 富途牛牛
Iovance Biotherapeutics' Q2 2025 Earnings Miss and Strategic Restructuring: A Turning Point or Deepening Crisis? - AInvest
Iovance Biotherapeutics Q2 Revenue Misses Estimates, Shares Plummet - AInvest
Iovance Biotherapeutics Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q2 2025 Earnings Call Transcript - Insider Monkey
Measuring Iovance Biotherapeutics Inc.’s beta against major indicesAlgorithmic Prediction of Market Breakouts - Newser
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates - MSN
Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (AVTX), Iovance Biotherapeutics (IOVA) and NextCure (NXTC) - The Globe and Mail
How to escape a deep drawdown in Iovance Biotherapeutics Inc.Free Step-by-Step Trade Signal Implementation - Newser
Reversal indicators forming on Iovance Biotherapeutics Inc. stockDownside Control Plan With Support Analysis - Newser
3 Stocks That Could Turn $1,000 Into $5,000 by 2030 - Mitrade
3 Stocks That Could Turn $1,000 Into $5,000 by 2030 - The Motley Fool
Key resistance and support levels for Iovance Biotherapeutics Inc.Free Capital Growth With Controlled Risk Picks - Newser
How to escape a deep drawdown in Iovance Biotherapeutics IncPredictive Screener for Daily Trade Watch - Newser
Is Iovance Biotherapeutics Inc. stock bottoming outReal Time Trade Execution Alert Plan - Newser
Real time social sentiment graph for Iovance Biotherapeutics Inc.Trading Volume Anomaly Summary and Insight - Newser
Why Iovance Biotherapeutics Stock Plummeted Today - AOL.com
IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi - sharewise.com
Iovance falls after missing Q2 expectation - MSN
Iovance falls after missing Q2 expectation (IOVA:NASDAQ) - Seeking Alpha
Iovance to Cut Staff by 20% Amid Slow Sales Start for Amtagvi Cell Therapy - AInvest
Iovance Biotherapeutics Reports Q2 Loss, Stock Down on EMA Filing Withdrawal for Amtagvi - AInvest
Goldman Sachs Downgrades Iovance Biotherapeutics Amid Lawsuit Turmoil - StocksToTrade
Iovance: Wells Fargo Maintains Overweight Rating, PT Down to $14 - AInvest
Iovance Shares Dip as CFO Changes and Legal Troubles Mount - timothysykes.com
Iovance Bio updates on Amtagvi - The Pharma Letter
Why Iovance Biotherapeutics Stock Is Under Pressure? - StocksToTrade
Is Iovance’s Stock Plummet A Buying Chance? - timothysykes.com
Chardan Capital Maintains Buy Rating on Iovance with PT Down to $20. - AInvest
Lacklustre Amtagvi launch forces Iovance to cut 19% of staff - FirstWord Pharma
Iovance Biotherapeutics: Q2 Earnings Snapshot - Connecticut Post
Building trade automation scripts for Iovance Biotherapeutics Inc.Daily Stock Forecast Powered by AI Tools - Newser
Earnings call transcript: Iovance Biotherapeutics Q2 2025 misses revenue forecast - Investing.com
Iovance Biotherapeutics Declines 29% In Premarket Trading: Here's What's Happening - Benzinga
Iovance Biotherapeutics Exceeds 100 Patient Milestone with Amtagvi Treatment for Advanced Melanoma, Q2 2025 Sales Reach $54 Million. - AInvest
Iovance Biotherapeutics shares fall 28.79% premarket after reporting a $111.7 million loss in Q2 2025. - AInvest
Iovance outlines $250M–$300M 2025 revenue target as restructuring aims to boost margins and expand Amtagvi adoption - MSN
Iovance Biotherapeutics (IOVA): Navigating Cost-Cutting and Global Expansion to Unlock Value in TIL Therapies - AInvest
Iovance Biotherapeutics: Strategic Restructuring and Amtagvi's Long-Term Potential in Immuno-Oncology - AInvest
Iovance Sets Revenue Target of $250M-$300M for 2025 Amid Restructuring Efforts to Boost Margins and Expand Amtagvi Adoption - AInvest
Iovance Biotherapeutics Inc (IOVA) Q2 2025 Earnings Call Highlig - GuruFocus
Transcript : Iovance Biotherapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Iovance Biotherapeutics Inc (IOVA) Q2 2025 Earnings Call Highlights: Revenue Surge and ... By GuruFocus - Investing.com Canada
How to forecast Iovance Biotherapeutics Inc. trends using time seriesTrade Flow Monitor with Volume Tracker - Newser
Iovance Biotherapeutics Reports Strong Revenue Growth in Q2 2025 - TipRanks
Iovance Biotherapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Iovance Biotherapeutics: Overcoming Revenue Shortfalls with Strategic Growth Initiatives - TipRanks
Bay Area biotech company once worth $4.4 billion lays off chunk of staff - SFGATE
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):